Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2025-01-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于子公司GenSci120注射液临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a clinical trial application for a subsidiary's pharmaceutical product. It details the drug, its indications, and the potential impact on the company. There are no financial statements, no regulatory certifications, no meeting materials, or voting results. The document is an official announcement of a regulatory approval related to clinical trials, which fits best under general regulatory announcements. It is not a financial report, management report, or any other specific filing type. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is under 5,000 characters and is an announcement, not a full report, so it is not a report publication announcement (RPA).
2025-01-16 Chinese
关于全资子公司签署战略合作协议暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a strategic cooperation framework agreement signed by a wholly-owned subsidiary of the company with a related party. It details the nature of the transaction, the parties involved, the board approval, and compliance with relevant regulations. There are no financial statements or detailed financial performance data presented. The document is relatively short (2808 characters) and serves as a disclosure of a related-party transaction and strategic cooperation agreement rather than a full financial report or detailed management discussion. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate transaction and compliance with listing rules, without constituting a full report or financial statement.
2025-01-06 Chinese
关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2025 first extraordinary general meeting (临时股东大会) of Changchun High-tech Industry Group Co., Ltd. It includes information about the meeting date, voting procedures, agenda items, and registration details. It does not contain financial statements or results but is a formal announcement to shareholders about the meeting and the proposals to be voted on. The document length is 3725 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-01-06 Chinese
第十一届董事会独立董事专门会议2025年第一次会议审核意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from the independent directors of the company's 11th board regarding a strategic cooperation framework agreement and related party transaction. It references compliance with laws and company regulations and expresses approval to submit the matter to the board meeting. There is no financial data, no report or results disclosed, and it is not an announcement of voting results or management changes. It is a board/management related document focused on governance and board-level decisions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and contains no financial statements or earnings data, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement as it contains substantive board meeting content and opinions.
2025-01-06 Chinese
第十一届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 8th meeting of the 11th Board of Directors of Changchun High-tech Industry (Group) Co., Ltd. It includes details about the meeting date, attendance, and voting results on specific proposals. It references other announcements for detailed content but itself is a summary of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document is short (774 characters) and does not contain financial statements or detailed reports, so it is not an Annual Report or Interim Report. It is not a voting result announcement (DVA) because it is about board meeting resolutions, not shareholder votes. Therefore, the correct classification is MANG with high confidence.
2025-01-06 Chinese
关于合作产品小儿黄金止咳颗粒在境内获批上市的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Changchun High-tech Industry Group Co., Ltd. regarding the approval of a cooperative product (a pediatric cough medicine) for market launch in China. It details the product information, cooperation details, and the expected impact on the company. There is no financial data, no mention of a report or filing, no regulatory certification, and no indication of a meeting or voting results. The document is a regulatory announcement about product approval and business impact, which fits best under general regulatory announcements that do not fit other categories.
2025-01-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.